Möchten Sie immer auf dem neuesten Stand bleiben?

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary...

LOUISVILLE, Ky., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Norton Neuroscience Institute is the first and only facility in Kentucky to offer MRI-guided high-frequency focused ultrasound for essential...

Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of...

Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be...

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...

Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of...

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...